Quanhecheng is a small molecule drug and IVD raw material CDMO platform, mainly engaged in drug molecular building blocks, drug intermediates, liquid crystal material monomers, process optimization, pilot and production services, as well as project process development technical services. Recently, Quanhecheng completed the 28 million A+ round of financing. The investors are Binhai Venture Capital, Zhongke Haihe Fund, and Binhai Intellectual Property Fund. This round of financing will be mainly used for the construction of the company’s production base and the research and development of new products, to help the company’s rapid transformation and layout of the chemical business to the biological sector, and to accelerate the production and transformation of the mRNA industry and the core raw material business of small nucleic acid drugs.
This article is reproduced from: https://www.itjuzi.com/investevent/13569365
This site is for inclusion only, and the copyright belongs to the original author.